Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: A double-blind, randomized, placebo-controlled, cross-over study

European Heart Journal

Volumn 33, Issue 13, 2012, Pages 1589-1597

  Enseleit, Frank ^a   Sudano, Isabella ^a   Périat, Daniel ^a   Winnik, Stephan ^a,b   Wolfrum, Mathias ^a   Flammer, Andreas J ^a   Fröhlich, Georg M ^a   Kaiser, Priska ^a   Hirt, Astrid ^a   Haile, Sarah R ^c   Krasniqi, Nazmi ^a   Matter, Christian M ^a,b   Uhlenhut, Klaus ^d   Högger, Petra ^d   Neidhart, Michel ^a   Lüscher, Thomas F ^a,b   Ruschitzka, Frank ^a   Noll, Georg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Clinical trial; Coronary artery disease; Endothelial function; Oxidative stress; Pycnogenol

Indexed keywords

6 N,N' DIMETHYLARGININE; ENDOTHELIN 1; ISOPROSTANE; PLACEBO; PYCNOGENOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEAR STRESS; THROMBOCYTE ADHESION; TREATMENT RESPONSE; ULTRASOUND; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ARGININE; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; SHEAR STRENGTH; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 84861417811     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr482     Document Type: Article

References (50)

1. Maritime Pine Extract. USP 34-NF 29 The United States Pharmacopeia and National Formulary. Maryland: The United States Pharmacopeial Convention Inc.; 2011. p1196-1197.
2. Rohdewald P. Pycnogenol. In: Rice-Evans C, Packer L, eds. Flavonoids in Health and Disease. New York: Marcel Dekker Ltd; 1998. p405-419.
3. Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 2004;36:811-822. (Pubitemid 38264423)
4. Das NP. Studies on flavonoid metabolism. Absorption and metabolism of (+)-catechin in man. Biochem Pharmacol 1971;20:3435-3445.
5. Sanchez-Patan F, Chioua M, Garrido I, Cueva C, Samadi A, Marco-Contelles J, Moreno-Arribas MV, Bartolome B, Monagas M. Synthesis, analytical features, and biological relevance of 5-(3′,4′-dihydroxyphenyl)-gamma- valerolactone, a microbial metabolite derived from the catabolism of dietary flavan-3-ols. J Agric Food Chem 2011;59:7083-7091.
6. Düweler KG, Rohdewald P. Urinary metabolites of French maritime pine bark extract in humans. Pharmazie 2000;55:364-368. (Pubitemid 30322228)
7. Grimm T, Skrabala R, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, Hogger P. Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers. BMC Clin Pharmacol 2006;6:4.
8. Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, Högger P. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond) 2006;3:1.
9. Schäfer A, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, Högger P. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60:5-9. (Pubitemid 41821211)
10. Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 1999;27:704-724. (Pubitemid 29408657)
11. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 1998;32:509-515. (Pubitemid 28440950)
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470. (Pubitemid 29135798)
13. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265. (Pubitemid 34084631)
14. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17. (Pubitemid 40128972)
15. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Luscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789-1796.
16. Faita F, Masi S, Loukogeorgakis S, Gemignani V, Okorie M, Bianchini E, Charakida M, Demi M, Ghiadoni L, Deanfield JE. Comparison of two automatic methods for the assessment of brachial artery flow-mediated dilation. J Hypertens 2011;29:85-90.
17. Gemignani V, Bianchini E, Faita F, Giannarelli C, Plantinga Y, Ghiadoni L, Demi M. Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol 2008;34:385-391. (Pubitemid 351625441)
18. Gemignani V, Faita F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. IEEE Trans Med Imaging 2007;26:393-404. (Pubitemid 46392347)
19. Wood WG, Ludemann J, Mitusch R, Heinrich J, Maass R, Frick U. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Clin Lab 2000;46:131-140. (Pubitemid 30162773)
20. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-1383. (Pubitemid 40057825)
21. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
22. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, Serafini M, Luscher TF, Ruschitzka F, Noll G, Corti R. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007;116:2376-2382. (Pubitemid 350145072)
23. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409.
24. Senn S. Cross-over Trials in Clinical Research. Chichester: John Wiley; 1993.
25. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20. (Pubitemid 9234327)
26. Holm S. A simple sequentially rejective multiple test procedure. Scand. J Statist 1979;6:65-70.
27. Kanai H, Hirakata H, Nakayama M, Nagashima A, Fujishima M. Minimal daily variations of plasma and urinary endothelin-1 in healthy subjects. Clin Nephrol 1996;46: 353-354. (Pubitemid 26390761)
28. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-1295. (Pubitemid 46594773)
29. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010;26:631-640.
30. Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, Goto C, Chayama K, Yoshizumi M, Higashi Y. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res 2007;30:775-780. (Pubitemid 47578238)
31. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010;31:2741-2748.
32. Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 2005;10(Suppl. 1):S24-S29.
33. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004;44:381-386. (Pubitemid 39281479)
34. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108: 1912-1916. (Pubitemid 37296532)
35. Roberts LJ 2nd, Morrow JD. Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 2002;59: 808-820. (Pubitemid 34628242)
36. Ryan J, Croft K, Mori T,Wesnes K, Spong J, Downey L, Kure C, Lloyd J, Stough C. An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol 2008;22:553-562.
37. Noda Y, Anzai K, Mori A, Kohno M, Shinmei M, Packer L. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997;42: 35-44. (Pubitemid 28172107)
38. Bayeta E, Lau BHS. Pycnogenol inhibits generation of inflammatory mediators in macrophages. Nutr Res 2000;20:249-259. (Pubitemid 30084528)
39. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-934. (Pubitemid 36026486)
40. Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010;7:105-118.
41. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005;43:1124-1129. (Pubitemid 41581972)
42. Mangoni AA. The emerging role of symmetric dimethylarginine in vascular disease. Adv Clin Chem 2009;48:73-94.
43. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, Atzler D, Grant PJ, Boger RH. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010;208:518-523.
44. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol 2006;176:249-283.
45. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci 2004;74:855-862. (Pubitemid 37501134)
46. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-168. (Pubitemid 34296383)
47. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000;57:834-841. (Pubitemid 30392039)
48. Hosseini S, Jeongmin L, Sepulveda RT, Rohdewald P, Watson RR. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res 2001;21:1251-1260. (Pubitemid 33041874)
49. Lau BH, Riesen SK, Truong KP, Lau EW, Rohdewald P, Barreta RA. Pycnogenol as an adjunct in the management of childhood asthma. J Asthma 2004;41:825-832. (Pubitemid 40019134)
50. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR. Pine bark extract reduces platelet aggregation. Integr Med 2000;2:73-77.